These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8438849

  • 1. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J, Genolla J, Ruibal A.
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995 Mar; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 5. A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders.
    Collazos J, Genollá J, Ruibal A.
    Scand J Clin Lab Invest; 1993 Oct; 53(6):633-7. PubMed ID: 8266011
    [Abstract] [Full Text] [Related]

  • 6. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB.
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [Abstract] [Full Text] [Related]

  • 7. Serum tumor markers in chronic liver disease.
    Kadayifci A, Simsek H, Savas MC, Toppare M.
    Neoplasma; 1996 Jan; 43(1):17-21. PubMed ID: 8843954
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.
    Collazos J, Genolla J, Ruibal A.
    Clin Chim Acta; 1992 Sep 15; 210(1-2):145-51. PubMed ID: 1424156
    [Abstract] [Full Text] [Related]

  • 10. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
    Jibiki K, Takeda M, Abe H, Ito M, Odagiri E, Demura R, Demura H, Takizawa K.
    Gan No Rinsho; 1990 Oct 15; 36(12):2146-52. PubMed ID: 2232183
    [Abstract] [Full Text] [Related]

  • 11. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar 15; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 12. [CA-125 in non-ovarian benign and malignant pathology: study on 380 patients].
    Marechal F, Berthiot G, Kritly T, Legrand MG, Deltour G, Cattan A.
    Bull Cancer; 1989 Mar 15; 76(7):697-706. PubMed ID: 2819261
    [Abstract] [Full Text] [Related]

  • 13. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C, Bei L, Liu T.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug 15; 20(4):285-8. PubMed ID: 11367693
    [Abstract] [Full Text] [Related]

  • 14. [Clinical evaluation of serum TAC-41 in various digestive cancers].
    Sato S, Yamanaka T, Kimura K.
    Rinsho Byori; 1989 Nov 15; 37(11):1259-62. PubMed ID: 2601083
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Nov 15; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 16. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Nov 15; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers.
    Kokociñska D, Jarzab B, Król R, Ziaja K, Szejbak K, Kuśmierski S.
    J Environ Pathol Toxicol Oncol; 1996 Nov 15; 15(2-4):283-7. PubMed ID: 9216823
    [Abstract] [Full Text] [Related]

  • 18. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
    Anticancer Res; 2002 Nov 15; 22(4):2311-6. PubMed ID: 12174919
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
    Lundin J, Roberts PJ, Kuusela P, Haglund C.
    Anticancer Res; 1995 Nov 15; 15(5B):2181-6. PubMed ID: 8572621
    [Abstract] [Full Text] [Related]

  • 20. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
    Nozawa S, Udagawa Y, Ito K, Nishimura H, Yakushiji M, Shiota M, Noda K, Yajima M, Ohkura H, Murae M.
    Gan To Kagaku Ryoho; 1994 Mar 15; 21(4):507-16. PubMed ID: 8129392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.